Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

Revenue projections:

Revenue projections for IPCALAB
Revenue projections for IPCALAB

IPCALAB's revenue projections indicate a decrease from last year's performance, which could lead to investor caution. A fall in revenue is likely to negatively impact the company's profitability, causing concern for shareholders who may view this as a signal of declining financial health.

Financial Ratios:

currentRatio 0.00000
forwardPE 32.22246
debtToEquity 14.80900
earningsGrowth 0.37900
revenueGrowth 0.09400
grossMargins 0.65304
operatingMargins 0.16239
trailingEps 28.73000
forwardEps 47.85000

IPCALAB's low Debt-to-Equity ratio reflects that the company isn't heavily reliant on debt, reducing financial risk. This conservative approach suggests IPCALAB maintains a stable financial foundation, with greater flexibility to manage future growth or challenges without over-leverage concerns.
Ipca Laboratories Limited's forward EPS exceeding its trailing EPS reflects expectations of increased profitability for the current year. This suggests that the company is projected to achieve higher earnings than in the previous financial year, signaling positive growth and improved financial health.

Price projections:

Price projections for IPCALAB
Price projections for IPCALAB

IPCALAB's price has often been near the lower end of the projected range. This ongoing trend suggests that investor confidence might be waning, and the stock could face challenges in gaining upward momentum.

Insider Transactions:

Insider Transactions for IPCALAB
Insider Transactions for IPCALAB


1 sales transactions of Ipca Laboratories Limited were conducted, with market price at 1513.199951171875.1 transactions to buy IPCALAB shares were recorded, with market price at 1189.6500244140625.The increased selling at Ipca Laboratories Limited's current price levels points to potential future declines. If this selling trend persists, the stock could face more downward pressure, suggesting investor pessimism about its future performance.

Recommendation changes over time:

Recommendations trend for IPCALAB
Recommendations trend for IPCALAB


Analysts' buy bias toward IPCALAB suggests the stock is seen as a solid investment, potentially motivating investors to consider it for their portfolios. With this positive outlook, IPCALAB is likely to be viewed as a secure place to allocate funds, driving further interest in the stock.